PharmaBlock (Stock Code: 300725.300725) is a global, fully integrated CRDMO in the pharmaceutical R&D and manufacturing industry. Its core businesses include a collection of rationally designed building blocks, supplying from discovery to development and commercialization; building block-enhanced hit generation and hit-to-lead optimization services and solutions; and development and manufacturing of RSMs, intermediates, APIs, and drug products for drug development and commercialization.
Throughout the product lifecycle, PharmaBlock integrates innovative and enabling technologies, such as flow chemistry, micropacked bed technology, chemo-catalysis, bio-catalysis, and equipment R&D, to proactively explore greener, safer, and more intelligent manufacturing and service models in the biopharmaceutical field, and promote the sustainable development of the industry.
Officially operated in 2008, PharmaBlock has partnered with almost all of the top 20 pharmaceutical companies, as well as hundreds of small to medium-sized biotech companies around the world. Its mission is to provide better products and services through innovation of chemistry and low-carbon technology in R&D and manufacturing, and help partners improve the efficiency of new drug discovery and development, and accelerate the project launch process at full speed.